Entries |
Document | Title | Date |
20080233650 | Method for propagating adenoviral vectors encoding inhibitory gene products - The invention provides a method of propagating an adenoviral vector. The method comprises (a) providing a cell comprising a cellular genome comprising a nucleic acid sequence encoding a tetracycline operon repressor protein (tetR), and (b) contacting the cell with an adenoviral vector comprising a heterologous nucleic acid sequence encoding a toxic protein. The heterologous nucleic acid sequence is operably linked to a promoter and one or more tetracycline operon operator sequences (tetO), and expression of the heterologous nucleic acid sequence is inhibited in the presence of tetR, such that the adenoviral vector is propagated. The invention also provides a system comprising the aforementioned cell and adenoviral vector. | 09-25-2008 |
20080241929 | METHOD AND MEANS FOR PRODUCING HIGH TITER, SAFE, RECOMBINANT LENTIVIRUS VECTORS - Lentiviral vectors modified at the 5′ LTR or both the 5′ and 3′ LTR are useful in the production of recombinant lentivirus vectors (See the Figure). Such vectors can be produced in the absence of a functional tat gene. Multiple transformation of the host cell with the vector carrying the transgene enhances virus production. The vectors can contain inducible or conditional promoters. | 10-02-2008 |
20080280363 | Pseudotyped Baculovirus and its Use - A viral G protein-pseudotyped baculovirus, in which the G protein is truncated and comprises the ectodomain, transmembrane domain and cytoplasmic tail domain. Such a baculovirus can be used for transduction of cells and for gene therapy. | 11-13-2008 |
20080286869 | Retroviral Vector - Provided herein is a retroviral vector comprising, and capable of expressing, a nucleotide of interest (NOI), wherein the NOI encodes an RNA or protein which is harmful to a cell. | 11-20-2008 |
20080293143 | Generation of human embryonc stem-like cells using intronic RNA - This invention generally relates to a method for developing, generating and selecting human embryonic stem (hES)-like pluripotent cells using transgenic expression of intronic microRNA-like RNA agents. More particularly, the present invention relates to a method and composition for generating a non-naturally occurring intron and its intronic components capable of being processed into mir-302-like RNA molecules in mammalian cells and thus inducing certain specific gene silencing effects on differentiation-related and fate-determinant genes of the cells, resulting in reprogramming the cells into a pluripotent embryonic stem (ES)-cell-like state. The ES-like cells so obtained are strongly express hES cell markers, such as Oct3/4, SSEA-3 and SSEA-4, and can be guided into various tissue cell types by treating certain hormones and/or growth factors under a feeder-free cell culture condition in vitro, which may be used for transplantation and gene therapies. Therefore, the present invention offers a simple, effective and safe gene manipulation approach for not only reprogramming somatic cells into ES-like pluripotent cells but also facilitating the maintenance of pluripotent and renewal properties of ES cells under a feeder-free cell culture condition, preventing the tedious retroviral insertion of four large transcription factor genes into one single cell as used in the previous iPS methods. | 11-27-2008 |
20080299660 | Methods For Transfecting Natural Killer Cells - Methods for stably transfecting mammalian natural killer cells comprising: transfecting a packaging cell line with a retroviral expression vector; culturing the transfected packaging cell line in a cell culture medium; and culturing the mammalian natural killer cells with the cell culture medium. Natural killer cells transfected according to the disclosed methods are also provided. | 12-04-2008 |
20080318320 | TARGETING VECTOR TO THE UROKINASE PLASMINOGEN ACTIVATOR RECEPTOR - The present invention relates to the targeted delivery of a delivery vehicle construct which specifically binds to and stimulates endocytosis into cells expressing the urokinase plasminogen activator receptor (uPAR), and particularly human airway epithelia. The delivery vehicle construct comprises a portion of uPA and a cargo linked thereto and is useful for the targeted delivery of the cargo to a cell. In one aspect of the invention, the uPA portion of the delivery vehicle construct comprises the wild-type uPA, a fragment of uPA which has the PAI-1 binding region deleted, or a uPA peptide comprising amino acids 13-19 and is useful for the targeted delivery of the cargo to cells, and in particular to airway epithelia. The present invention also provides a method for delivering the delivery vehicle construct to a cell. The method comprises the steps of (a) contacting a target cell with a delivery vehicle construct comprising a uPA portion and a cargo portion; and (b) obtaining a desired result in the target cell. | 12-25-2008 |
20090017543 | Viral Vectors - The present invention relates to an integration defective retroviral vector particle for gene therapy comprising a viral genome, wherein said vector particle is capable of infecting a mammalian target cell. | 01-15-2009 |
20090042299 | Vectors and methods for tissue specific synthesis of proteins in eggs of transgenic hens - Vectors and methods are provided for introducing genetic material into cells of a chicken or other avian species. More particularly, vectors and methods are provided for transferring a transgene to an embryonic chicken cell, so as to create a transgenic hen wherein the transgene is expressed in the hen's oviduct and the transgene product is secreted in the hen's eggs and/or those of her offspring. In a preferred embodiment, the transgene product is secreted in the egg white. | 02-12-2009 |
20090117658 | Macrophage transfection method - Described are a method and a composition for transfecting monocytes, as well as use of the same for therapeutic purposes. The composition is composed of a nucleic acid component, a lysosome evading component and a digestible particle that can be phagocytized. Preferably, the monocyte is a macrophage and the digestible particle is from a natural source, such as from a microbial source. More preferably, the digestible particle is a yeast cell wall particle such as zymosan. The composition itself, or cells pretreated with the composition, are useful in all gene medicine applications, such as gene therapy, gene vaccination, cancer treatment as well as immunomodulation and tissue repair. | 05-07-2009 |
20090148949 | rAAV Expression Systems and Methods of Use - Disclosed are improved VP2-modified recombinant adeno-associated viral (rAAV) vectors, expression systems, and rAAV virions that are fully virulent, yet lack functional VP2 protein expression. Also disclosed are pharmaceutical compositions, virus particles, host cells, and pharmaceutical formulations that comprise these modified vectors useful in the expression of therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in the cells and tissues of selected mammals, including, for example, human tissues and host cells. | 06-11-2009 |
20090162936 | Method For Transfer Of Gene Into Fat Cell Or Progenitor Fat Cell - A method for transferring a gene into a fat cell or progenitor fat cell comprising the step of infecting the fat cell or progenitor cell with a retrovirus vector having a foreign gene in the presence of a substance having both of a retrovirus-binding site and a target cell-binding site in the molecule or a mixture of a substance having a retrovirus-binding site and a substance having a target cell-binding site, the target cell-binding site having a region that can bind to VLA-5 and/or a region that can bind to VLA-4. | 06-25-2009 |
20090162937 | COMPOSITIONS AND METHODS COMPRISING THE USE OF CELL SURFACE DISPLAYED HOMING ENDONUCLEASES - According to particular exemplary aspects, DNA target site binding and cleavage properties of native, variant or modified homing endonucleases (HE) (e.g., LAGLIDAG (LHE), HNH, His-Cys Box, GIY-YIG, I-SspI-type, and fusions, muteins or variants thereof) in solution are recapitulated on the cell surface (e.g., as assessed by flow cytometric analysis) to provide for novel cells expressing one or more cell surface HEs (e.g., expressing one or more HE binding and/or cleavage specificities), novel cell libraries, and high-throughput methods for assessing target site binding, target site cleavage. The rapid analysis of HE and LHE-DNA interactions on the cell surface with concurrent sorting options provides for high-throughput library screening affording rapid identification, analysis and isolation of novel HEs or LHEs having novel sequence specificities. Such novel sequence specificities, obtained by said methods provide novel methods for introducing targeted DNA-strand cleavage events, and novel chromatin immunoprecipitation methods (CHIP methods). | 06-25-2009 |
20090203141 | Generation of tumor-free embryonic stem-like pluripotent cells using inducible recombinant RNA agents - The present invention generally relates to a method for developing, generating and selecting tumor-free embryonic stem (ES)-like pluripotent cells using electroporation delivery of an inducible tumor suppressor mir-302 agent into mammalian cells. More particularly, the present invention relates to a method and composition for generating a Tet-On/Off recombinant transgene capable of expressing a manually re-designed mir-302 microRNA (miRNA)/shRNA agent under the control of doxycyclin (Dox) in human somatic/cancer cells and thus inducing certain specific gene silencing effects on the differentiation-associated genes and oncogenes of the cells, resulting in reprogramming the cells into an ES-like pluripotent state. | 08-13-2009 |
20090221077 | Process for producing cytotoxic lymphocytes - The present invention provides a method for preparing a cytotoxic lymphocyte characterized in that the method comprises the step of carrying out at least one step selected from induction, maintenance and expansion of a cytotoxic lymphocyte using a medium containing serum and plasma at a total concentration of 0% by volume or more and less than 5% by volume, in the presence of fibronectin, a fragment thereof or a mixture thereof. | 09-03-2009 |
20090253208 | Recombinant Viral Vector for Gene Transfer into Lymphoid Cells - A recombinant herpesvirus, a method for producing the recombinant herpesvirus, and a pharmaceutical composition comprising the recombinant herpesvirus, are provided with a method for producing a recombinant herpesvirus using a BAC vector sequence. In addition, a vector comprising a herpesvirus genomic gene and a BAC vector sequence, a cell comprising the vector, and a nucleic acid cassette comprising a fragment, which is capable of homologous recombination with a herpesvirus genome, and a BAC vector sequence, are provided. | 10-08-2009 |
20090269850 | Mutant Paramyxovirus and Method for Production Thereof - The present invention provides a modified paramyxovirus containing a reduced amount of receptor-binding protein compared with the wild type; a method of preparing a modified paramyxovirus, comprising the following steps: (1) a step for introducing a nucleic acid that suppresses the expression of a receptor-binding protein of a paramyxovirus into an animal cell, (2) a step for infecting the paramyxovirus to the cell, and (3) a step for isolating paramyxovirus particles replicated in the cell; and a modified paramyxovirus prepared by the method of preparation mentioned above. | 10-29-2009 |
20090286321 | METHODS FOR TARGETING MODIFIED RAAV VECTORS TO MAMMALIAN CELLS - Disclosed are improved VP2-modified recombinant adeno-associated viral (rAAV) vectors, expression systems, and rAAV virions that are fully virulent, yet lack functional VP2 protein expression. Also disclosed are pharmaceutical compositions, virus particles, host cells, and pharmaceutical formulations that comprise these modified vectors useful in the expression of therapeutic proteins, polypeptides, peptides, antisense oligonucleotides and/or ribozymes in the cells and tissues of selected mammals, including, for example, human tissues and host cells. | 11-19-2009 |
20100062534 | INDUCIBLE LENTIVIRAL VECTORS FOR REPROGRAMMING SOMATIC CELLS - Described herein is a method for reprogramming a somatic cell using an inducible lentiviral vector that permits the expression of stem-cell associated genes to be turned off or on as necessary by one of skill in the art. Inducible expression of stem-cell associated genes permits the genes to be expressed until such time that induction of iPS cells occurs and then expression can be turned off to prevent the pathological growth of cells leading to e.g., cancer or teratoma. Also described herein are secondary cell compositions, the use of which can speed the production of iPS cells, providing for a faster, more efficient system for iPS cell induction. | 03-11-2010 |
20100129915 | METHODS FOR INDUCING CARDIOMYOGENESIS - The present invention provides methods of inducing cardiomyogenesis and expansion of cardiac progenitors in a population of stem cells or progenitor cells, the methods generally involving inducing a canonical Wnt signaling pathway in the stem cells or progenitor cells. The present invention provides methods of generating a population of cardiomyocytes or cardiac progenitors from a population of stem cells or progenitor cells, the methods generally involving contacting the stem cells or progenitor cells with an agent that induces canonical Wnt signaling. A subject method is useful for generating a population of cardiomyocytes or cardiac progenitors, which can be used in research and therapeutic applications. | 05-27-2010 |
20100151576 | TARGETED TUMOR THERAPY BY USE OF RECOMBINANT ADENOVIRUS VECTORS THAT SELECTIVELY REPLICATE IN HYPOXIC REGIONS OF TUMORS - The presently claimed subject matter provides conditionally replication competent adenoviral vectors that confer selective cytotoxicity on cells expressing HIF-1 by infecting cells that allow HIF-1 inducible promoters present within the vectors to function. Also provided are compositions and host cells based upon the vectors, as well as methods of propagating and using the vectors. The presently claimed subject matter further provides a method of inhibiting tumor growth by co-infecting cells in a tumor with a conditionally replication competent adenovirus vector in conjunction with a replication deficient adenovirus vector. | 06-17-2010 |
20100267145 | IMMUNOCOMPETENT CELL HAVING ANTI-CD38 ANTIBODY ON ITS CELL SURFACE - An immunocompetent cell expressing an anti-CD38 antibody on its surface through genetic introduction of a DNA coding for part of the anti-CD38 antibody; and a method of producing an immunocompetent cell expressing the antibody on its cell surface, which includes amplifying a cDNA using the mRNA coding for part of the anti-CD38 antibody isolated from a hybridoma, inserting the amplified cDNA into a retroviral vector, transfecting the vector into a packaging cell to produce a packaging cell capable of producing an anti-CD38 antibody expressing-retroviral particle, and infecting a human immunocompetent cell with the retroviral particle released from the packaging cell. | 10-21-2010 |
20100267146 | METHOD FOR EXPRESSION OF SMALL ANTIVIRAL RNA MOLECULES WITH REDUCED CYTOTOXICITY WITHIN A CELL - In one aspect, the invention provides methods and compositions for the expression of small RNA molecules within a cell using a retroviral vector (FIG. | 10-21-2010 |
20100273265 | REGENERATION AND NEOGENESIS OF RETINAL PHOTORECEPTOR CELL USING OTX2 GENE - The present invention provides a medicine, comprising (a) an Otx2 protein or its partial peptide, or a salt thereof, or (b) a DNA or an RNA encoding an Otx2 protein or its partial peptide. The present medicine is useful as an agent for preventing, treating or suppressing progression of a retinal disease including retinal degeneration. In addition, the present medicine is useful, for example, as an agent for inducing differentiation from a retinal stem cell into a retinal photoreceptor cell, in the transplantation of a cell into the retina of patients suffering from retinal diseases. | 10-28-2010 |
20100279416 | METHOD FOR INTRODUCING CHANGES INTO A EUKARYOTIC GENOME IN VIVO AND A KIT - The invention relates to a method for introducing changes into a eukaryotic genome in vivo wherein the HPV genome, which comprises HPV replication origin sequence, is used together with HPV early proteins in order to achieve DNA replication in vivo. There is also disclosed a kit for in vivo amplification, excision, translocation and/or inversion of a DNA sequence, which comprises a vector carrying HPV genome or a part of HPV genome including HPV replication origin sequence, and expression vector or vectors encoding HPV early proteins. | 11-04-2010 |
20100311171 | VECTORS FOR GENERATING PLURIPOTENT STEM CELLS AND METHODS OF PRODUCING PLURIPOTENT STEM CELLS USING THE SAME - Stem cell reprogramming genes cloned into a single sustained expression-type Sendai viral vector are shown to reprogram differentiated somatic cells into induced pluripotent stem (iPS) cells without integration of vector sequences into the host cell's genome. The genes are transduced into normal differentiated somatic cells via infection with recombinant Sendai virus. After expression of the reprogramming genes and subsequent induction of pluripotency, the vector genome RNA including the reprogramming genes is removed from the cell to establish an iPS cell that is genetically identical to the parent somatic differentiated cell thus reducing the risk of tumorigenic transformation caused by random integration of vector sequences into the host genome. The method promises to provide safe, autologous iPS cells that can be used for human cell replacement and regeneration therapeutic applications. | 12-09-2010 |
20110059531 | METHOD FOR EXPRESSION OF SMALL RNA MOLECULES WITHIN A CELL - The invention provides methods and compositions for the expression of small RNA molecules within a cell using a lentiviral vector. The methods can be used to express doubles stranded RNA complexes. Small interfering RNA (siRNA) can be expressed using the methods of the invention within a cell, which are capable of down regulating the expression of a target gene through RNA interference. A variety of cells can be treated according to the methods of the invention including embryos, embryogenic stem cells, allowing for the generation of transgenic animals or animals constituted partly by the transduced cells that have a specific gene or a group of genes down regulated. | 03-10-2011 |
20110070651 | RECOMBINANT VIRAL VECTOR FOR GENE TRANSFER INTO LYMPHOID CELLS - A recombinant herpesvirus, a method for producing the recombinant herpesvirus, and a pharmaceutical composition comprising the recombinant herpesvirus, are provided with a method for producing a recombinant herpesvirus using a BAC vector sequence. In addition, a vector comprising a herpesvirus genomic gene and a BAC vector sequence, a cell comprising the vector, and a nucleic acid cassette comprising a fragment, which is capable of homologous recombination with a herpesvirus genome, and a BAC vector sequence, are provided. | 03-24-2011 |
20110104805 | Pluripotent Stem Cells - The present invention provides methods to produce pluripotent stem cells from adult cells. In particular, the present invention provides methods to produce pluripotent stem cells from somatic cells without the use of a feeder-cell layer or an agent that increases efficiency of retroviral transfection. | 05-05-2011 |
20110129928 | Method of Manufacturing Induced Pluripotent Stem Cell Originated from Somatic Cell - Disclosed is a method for manufacturing stem cells including preparing Oct-4 gene, Sox2 gene, C-myc gene, and Klf-4 gene from mouse embryonic stem cells, and allowing each of the genes to be infected in host cells using a lentiviral vector system to generate viruses in which each of the genes are induced; concentrating or mixing each of the viruses to prepare a virus concentrated mixture, and mixing the virus concentrated mixture and a first culture solution to prepare a virus solution; floating mouse somatic cells having been cultivated in advance in a first culture dish, and mixing and reacting the floated somatic cells and the virus solution to prepare a somatic cell-virus mixture; adding and retaining the somatic cell-virus mixture as is in a second culture dish including a second culture solution to induce the genes in the somatic cells; and cultivating the somatic cells. | 06-02-2011 |
20110165683 | CHIMERIC GAMMARETROVIRUS - The invention is directed to a chimeric gammaretrovirus comprising an gammaretroviral virion which contains a lentiviral Vpx protein and methods of use thereof. | 07-07-2011 |
20110250694 | EUKARYOTIC EXPRESSION VECTORS RESISTANT TO TRANSGENE SILENCING - The present invention relates to recombinant DNA molecules such as plasmids, non-viral vectors, viral vectors and hybrids thereof, and more particularly to vector modifications that improve expression of said DNA molecules in cell lines and organisms. | 10-13-2011 |
20110263027 | Adeno-associated virus (AAV) sequences and isolating novel sequences identified thereby - Adeno-associated virus 7 sequences, vectors containing same, and methods of use are provided. | 10-27-2011 |
20110269235 | METHODS FOR CULTURING MAMMALIAN TASTE CELLS - The invention provides methods of culturing mammalian taste cells, including taste receptor cells. Cells are maintained for a duration of up to three months and longer while maintaining molecular and functional characteristics of mature taste cells. The cells are cultured on coated cell culture vessels and, from first replacement of medium onwards, the medium is replaced in intervals of at least 5 days. The invention further provides isolation and culturing methods of taste cells wherein the time that the cells are exposed to isolation solution and proteolytic enzymes is minimized and the cells are cultured in coated culture vessels with the medium replaced in intervals of at least 5 days from first replacement onwards. The invention further provides cultured taste cells, transfection and assay methods, and taste cell assay buffers with an osmolarity of about 300-320 and pH of about 7.0-7.3. | 11-03-2011 |
20120028358 | METHOD FOR INCREASING RETROVIRAL INFECTIVITY - The present invention is directed to methods for enhanced retroviral delivery of a nucleic acid to a target cell in vitro, ex vivo or in vivo, which involves increasing infectivity of a retrovirus carrying a transgene of interest to a target cell. In one particular aspect the invention relates to a method for increasing retroviral infectivity of target cells comprising culturing packaging cells transfected with retroviral vector containing a transgene of interest in medium containing a glucocorticoid receptor agonist or analog or derivative thereof present in the medium in an amount effective to increase titer of propagated retrovirus; and subsequently culturing a target cell in medium comprising the propagated retrovirus from a) and a glucocorticoid receptor antagonist or analog or derivative thereof present in the medium in an amount effective to increase target cell sensitivity to infection by the propagated retrovirus. | 02-02-2012 |
20120070899 | EFFECTIVE VECTOR PLATFORM FOR GENE TRANSFER AND GENE THERAPY - The invention relates to the discovery that mutations of serine residues of an AAV capsid results in significantly greater transfection efficiency than the wild type AAV2 virus. In one embodiment, the present invention provides a method of improving efficiency of gene transfer and/or gene therapy to a cell by inhibiting phosphorylation of one or more serine residues of a virus capsid protein, where the inhibition of the phosphorylation of one or more serine residues results in a decrease of ubiquitination of the virus capsid protein in the cell. In another embodiment, one of the one or more serine residues is Serine 264. In another embodiment, the Serine 264 residue is mutated to Alanine (S 264 A). | 03-22-2012 |
20120129263 | RECOMBINANT VIRAL VECTOR FOR GENE TRANSFER INTO LYMPHOID CELLS - A recombinant herpesvirus, a method for producing the recombinant herpesvirus, and a pharmaceutical composition comprising the recombinant herpesvirus, are provided with a method for producing a recombinant herpesvirus using a BAC vector sequence. In addition, a vector comprising a herpesvirus genomic gene and a BAC vector sequence, a cell comprising the vector, and a nucleic acid cassette comprising a fragment, which is capable of homologous recombination with a herpesvirus genome, and a BAC vector sequence, are provided. | 05-24-2012 |
20120202291 | SIMPLIFIED BASIC MEDIA FOR HUMAN PLURIPOTENT CELL CULTURE - Fully defined media that support pluripotent cell viability, proliferation, cloning, and derivation, as well as methods and compositions including these media are described. Methods for deriving iPS cells from adult individuals under defined, xeno-free conditions are also described. | 08-09-2012 |
20120214240 | VECTORS FOR GENERATING PLURIPOTENT STEM CELLS AND METHODS OF PRODUCING PLURIPOTENT STEM CELLS USING THE SAME - A reprogramming gene-loaded Sendai viral vector comprising Sendai virus genes and reprogramming genes, wherein the Sendai virus genes include an NP gene, P/C gene, M gene, F gene, HN gene and L gene, wherein each of the M gene, the F gene and the FIN gene is from a Sendai virus strain Cl.151-derived gene and wherein at least one of the M gene, the F gene and the HN gene is functionally deleted and the L gene encodes the amino-acid sequence of the L protein in which the amino-acid residue at position 1618 is valine and a method of producing the same. | 08-23-2012 |
20120258540 | METHODS FOR MODIFYING VIRUS SURFACES - Nucleic acid delivery vehicles and methods of their use are provided. One embodiment provides a virus having a lipid-polymer conjugate intercalated into the virus's membrane. The lipid-polymer conjugate includes a biocompatible polymer having first and second ends, a lipid conjugated to the first end, and a targeting moiety conjugated to the second end. The lipid is preferably a multi-chain lipid. The virus encodes one or more polypeptides that can help reduce or mitigate one or more symptoms of a disease or pathology. The lipid-polymer conjugate advantageously reduces non-specific binding of the virus while the targeting moiety enhances binding to specific cells or tissues. | 10-11-2012 |
20120301965 | CELL PROGRAMMING - The present invention is concerned with methods for reprogramming of mammalian somatic cells and in particular to reprogramming of mature mammalian somatic cells into multi-potent precursor cells. | 11-29-2012 |
20130109096 | METHOD FOR GENE TRANSFER | 05-02-2013 |
20130122591 | METHODS AND COMPOSITIONS FOR MODIFICATION OF THE HPRT LOCUS - Nucleases and methods of using these nucleases for modification of an HPRT locus and for increasing the frequency of gene modification at a targeted locus and clones and for generating animals. | 05-16-2013 |
20130130386 | MODIFIED DENDRITIC CELLS HAVING ENHANCED SURVIVAL AND IMMUNOGENICITY AND RELATED COMPOSITIONS AND METHODS - Modified antigen presenting cells provided herein have improved lifespan and immunogenicity compared to unmodified antigen presenting cells, and are useful for immunotherapy. The modified antigen presenting cells express an altered protein kinase, referred to herein as “Akt.” The altered Akt associates with the cell membrane with greater frequency than unaltered Akt, and is referred to herein as “membrane-targeted Akt.” | 05-23-2013 |
20130130387 | METHOD FOR GENERATING INDUCED PLURIPOTENT STEM CELLS FROM KERATINOCYTES DERIVED FROM PLUCKED HAIR FOLLICLES - A method for generating induced pluripotent stem (iPS) cells from isolated hair follicles is disclosed. The method comprises:
| 05-23-2013 |
20130157368 | INDUCED PLURIPOTENT STEM CELLS PREPARED FROM HUMAN KIDNEY-DERIVED CELLS - We have disclosed an induced pluripotent stem cell and the method of preparing the induced pluripotent stem cell from a human kidney-derived cell. More particularly, we have disclosed a human kidney-derived iPS cell which may be differentiated into cells of ectoderm, mesoderm, and endoderm lineages. | 06-20-2013 |
20130189786 | METHOD FOR PRODUCING INDUCED PLURIPOTENT STEM CELLS - An object of the present invention is to provide methods for producing iPS cells with low invasivity and high efficiency. The iPS cells can be produced with high efficiency using a method comprising the steps of culturing mononuclear cells derived from peripheral blood for 3 to 14 days in the presence of anti-CD3 antibody, and subjecting the cultured mononuclear cells to dedifferentiation. | 07-25-2013 |
20130210150 | COMPOSITION FOR INDUCING PLURIPOTENT STEM CELL, AND USE THEREOF - The present invention provides Sendai virus vectors in which genes that encode reprograming factors for inducing pluripotent stem cells are incorporated in a specific order, compositions comprising these vectors for gene delivery to be used in the induction of pluripotent stem cells, and uses thereof. Incorporation of the KLF gene, OCT gene, and SOX gene in a specific order into a single Sendai virus vector successfully and significantly increased the efficiency of pluripotent stem cell induction. Loading multiple reprogramming factors into a single vector can further increase the induction efficiency of pluripotent stem cells while reducing the number of necessary vectors. | 08-15-2013 |
20130244330 | Novel Substitution Mutant Receptors and Their Use in a Nuclear Receptor-Based Inducible Gene Expression System - This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a Group H nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms. | 09-19-2013 |
20130267029 | MANIPULATION OF STEM CELL FUNCTION BY P53 ISOFORMS - This invention provides methods and compositions for increasing the efficiency of obtaining pluripotent stem cells, the method comprising expressing a 133p53 in cells that are being re-programmed to obtain pluripotent cells. The invention also provides method of inhibiting the proliferation of cancer stem cells, the method comprising suppressing expression of 133p53 in the cells. | 10-10-2013 |
20130316456 | CELL TRANSDIFFERENTIATION INTO BROWN ADIPOCYTES - A method for converting animal cells into brown adipose tissue cells is provided that includes transforming the animal cells using an expression vector. The expression vector includes a nucleotide sequence encoding HB-EGF operatively linked to a promoter and a nucleotide sequence encoding ADAM 12 operatively linked to a promoter. Converting animal cells to brown adipose tissue cells can be used to treat obesity or to treat cancer by converting target cells to brown adipose tissue cells. | 11-28-2013 |
20140011281 | Direct Reprogramming of Cells to Cardiac Myocyte Fate - A method for promoting conversion of cells into cardiomyocytic tissue is carried out by contacting fibrotic tissue (e.g., scar tissue) with a microRNA oligonucleotide or combination of microRNA oligonucleotides. The methods lead to direct reprogramming of fibroblasts to cardiomyocytes or cardiomyoblasts. | 01-09-2014 |
20140017792 | VECTOR PARTICLES FOR TARGETING CD34+ CELLS - The present invention relates to a vector particle for transferring biological material into cells, wherein said vector particle comprises at least:
| 01-16-2014 |
20140051171 | CONVERSION OF SOMATIC CELLS TO INDUCED REPROGRAMMED NEURAL STEM CELLS (IRNSCS) - This application relates to a method for converting somatic cells to Neural Stem Cells (NSCs). Moreover this application relates to a method for converting human fibroblasts, keratinocytes or adipocytes to neural stem cells based on linked steps of genes transduction and chemically defined medium induction. | 02-20-2014 |
20140057354 | ANTIGEN-SPECIFIC REGULATORY T-CELL INDUCTION - The present invention relates to an infectious particle having a surface displaying a ligand binding to a CD4 receptor for selectively infecting dividing CD4 | 02-27-2014 |
20140170752 | GENERATION OF iPS CELLS AND ASSOCIATED METHODS - Systems, constructs, and methods for reprogramming cells are provided. In one aspect, for example, a transformation construct for generating iPS cells can include an expression vector having a plurality of reprogramming factors, each reprogramming factor being under control of a separate promoter. | 06-19-2014 |
20140193912 | METHOD FOR INCREASING THE EFFICIENCY OF INDUCING PLURIPOTENT STEM CELLS - The present invention relates to a method for increasing the efficiency of inducing pluripotent stem cells by utilizing genes Jhdm1a that modify histone. By utilizing Jhdm1a, and a stem cell inducing factor, the present invention increases the efficiency of inducing pluripotent stem cells and increases the quality of induced pluripotent stem cells. The stem cell inducing factor is a combination of Oct4 and Klf4, or a combination of Sox2, Oct4, and Klf4, or a combination of Oct4 and Sox2, and Oct4 alone. The method further comprises exposing the cells to vitamin C, which further increases the efficiency of inducing pluripotent stem cells as compared with the case where no vitamin C is used. By using less stem cell reducing factors, the method of the present invention reduces the potential carcinogenicity, obtains a high inducing efficiency, and provides high-quality induced pluripotent stem cells capable of germ-line transmission. | 07-10-2014 |
20140234971 | Induction of Hemogenic Endothelium from Pluripotent Stem Cells - Described herein are methods and related compositions for inducing differentiation of human pluripotent stem cells (hPSCs) into hemogenic endothelium with pan-myeloid potential or restricted potential, by forced expression in the hPSCs of a combination of transcription factors as described herein. | 08-21-2014 |
20140234972 | CRISPR-CAS Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes - The invention provides for systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are vectors and vector systems, some of which encode one or more components of a CRISPR complex, as well as methods for the design and use of such vectors. Also provided are methods of directing CRISPR complex formation in eukaryotic cells and methods for selecting specific cells by introducing precise mutations utilizing the CRISPR/Cas system. | 08-21-2014 |
20140273228 | METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING INHIBITORY GENE PRODUCTS - The invention provides a method of propagating an adenoviral vector. The method comprises (a) providing a cell comprising a cellular genome comprising a nucleic acid sequence encoding a tetracycline operon repressor protein (tetR), and (b) contacting the cell with an adenoviral vector comprising a heterologous nucleic acid sequence encoding a toxic protein. The heterologous nucleic acid sequence is operably linked to a promoter and one or more tetracycline operon operator sequences (tetO), and expression of the heterologous nucleic acid sequence is inhibited in the presence of tetR, such that the adenoviral vector is propagated. The invention also provides a system comprising the aforementioned cell and adenoviral vector. | 09-18-2014 |
20140287511 | USE OF ZSCAN4 AND ZSCAN4-DEPENDENT GENES FOR DIRECT REPROGRAMMING OF SOMATIC CELLS - Disclosed herein is the finding that Zscan4 is an early embryonic factor that facilitates cellular reprogramming. In particular, Zscan4 can replace the oncogenic reprogramming factor c-Myc to produce induced pluripotent stem cells when co-expressed with Klf4, Oct4 and Sox2. In addition, several Zscan4-dependent genes were identified that promote iPSC formation when co-expressed with known reprogramming factors. Thus, the present disclosure provides an ex vivo method of producing an iPS cell by reprogramming of a somatic cell. The method includes contacting the somatic cell with a Zscan4, or a Zscan4-dependent gene, and at least one reprogramming factor. Also provided are iPS cells produced by the disclosed method and non-human animals generated from such iPS cells. | 09-25-2014 |
20140287512 | METHOD OF CULTIVATING CELLS ON MICROCARRIERS IN A BAG - A method of cultivating cells in a bag is disclosed, which comprises the steps of: | 09-25-2014 |
20140302609 | POLYDNAVIRUS DELIVERY CONSTRUCTS - Provided herein are methods of producing a genetically modified cell by introducing a polydnavirus delivery construct to a target cell. The polydnavirus delivery construct can comprise an exogenous nucleic acid to form a genetically modified cell comprising the exogenous nucleic acid. Also provided are polydnavirus delivery constructs comprising an exogenous nucleic acid, as well as polydnavirus virions and genetically modified cells comprising the same. Further provided are in vitro methods of identifying a transformed cell. The methods comprise introducing a vector comprising a nucleotide sequence encoding a glc polypeptide to an adherent cell and cultivating the cell under conditions that allow for the expression of the glc polypeptide. Expression of the glc polypeptide results in a transformed cell that is identified by a loss of adherency. | 10-09-2014 |
20140322813 | METHODS AND COMPOSITIONS FOR ENHANCING THE EFFICACY AND SPECIFICITY OF RNA SILENCING - The present invention provides methods of enhancing the efficacy and specificity of RNA silencing. The invention also provides compositions for mediating RNA silencing. In particular, the invention provides siRNAs, siRNA-like molecules, shRNAs, vectors and transgenes having improved specificity and efficacy in mediating silencing of a target gene. Therapeutic methods are also featured. | 10-30-2014 |
20140335620 | ENGINEERING AND OPTIMIZATION OF IMPROVED SYSTEMS, METHODS AND ENZYME COMPOSITIONS FOR SEQUENCE MANIPULATION - The invention provides for engineering and optimization of systems, methods, and compositions for manipulation of sequences and/or activities of target sequences. Provided are compositions and methods related to components of a CRISPR complex particularly comprising a Cas ortholog enzyme. | 11-13-2014 |
20140349404 | METHOD FOR GENE TRANSFER - Disclosed is a simple and highly efficient method for introducing a gene into a target cell using a retrovirus vector. The method comprises the steps of (a) placing a liquor containing a retrovirus vector having a foreign gene carried thereon into a bag for cell culture on which a retrovirus-binding substance has been immobilized, and incubating the liquor at a temperature lower than 25° C. for 8-48 hours, thereby producing a culture bag having the retrovirus vector bound thereto, (b) adding a target cell to the culture bag that has been produced in step (a) and incubating the culture bag for 8 hours or less, and (c) flipping the culture bag upside down and incubating the culture bag. The gene introduction method is useful particularly in medicine, cell technology, gene technology, and embryologic technology. | 11-27-2014 |
20140370602 | TROPHECTODERMAL CELL-SPECIFIC GENE TRANSFER METHODS - The present inventors discovered that genes could be introduced specifically into trophectodermal cells with high efficiency, by infecting blastocysts with viral vectors carrying an arbitrary polynucleotide, or by using a nucleic acid transfection reagent in blastocysts, from which zona pellucida (extracellular matrix covering preimplantation early embryos to protect them from infection of viruses and the like) is removed. This method has no risk of infecting cells of the inner cell mass, which develops into a fetus in the future, with the introduced polynucleotide because the trophectoderm serves as a barrier. The present invention provides methods for introducing foreign genes into only placenta but not fetus, which enables rescue of genetically mutant animals from embryonic lethality due to placental abnormality and allows their birth. Furthermore, it is possible to analyze expression and effect of genes that regulate placental formation or placental function by using these methods. | 12-18-2014 |
20140377870 | METHOD FOR INSERTING GENETIC MATERIAL INTO GENOMIC DNA - The present invention provides reagents and methods for improved homologous recombination. | 12-25-2014 |
20150011006 | LENTIVIRAL TRIPLEX DNA, AND VECTORS AND RECOMBINANT CELLS CONTAINING LENTIVIRAL TRIPLEX DNA - The present invention provides nucleic acid, vectors, viruses, and recombinant cells comprising triple-stranded structures, such as those resulting from central initiation and termination of HIV-1 reverse transcription at the center of HIV-1 linear DNA genomes. These triplex structures can act as a cis-determinant of HIV-1 DNA nuclear import, allowing infection of non-dividing target cells. In one aspect, the presence of the DNA triplex sequence in an HIV vector strongly stimulates gene transfer in hematopoietic stem cells. The invention also provides methods of using these triplex structures for making recombinant cells, as well as methods of using the recombinant cells to express proteins of interest both in vitro and in vivo. | 01-08-2015 |
20150037891 | METHODS FOR ENHANCING INFECTIVITY OF RETROVIRUSES - The present invention provides methods for producing retroviruses or viral vectors with enhanced infectivity. The methods entail transfecting a retroviral vector into a packaging cell that has suppressed expression or inhibited enzymatic activity of a parvulin prolyl peptidyl isomerase (parvulin PPIase), and culturing the transfected packaging cell to allow production of viral particles. The invention also provides methods for enhancing efficiency of gene transfer with a recombinant retrovirus. These methods involve constructing a recombinant retroviral vector expressing a target gene, transfecting into a packaging cell that has suppressed expression or inhibited enzymatic activity of a parvulin prolyl peptidyl isomerase (parvulin PPIase), culturing the transfected packaging cell to allow production of recombinant retroviral particles, harvesting recombinant retroviral particles from supernatant of the cultured cell, and transducing the recombinant retroviral particles into a target cell. Kits for carrying out these methods are also provided in the invention. | 02-05-2015 |
20150064788 | RETROVIRAL TRANSDUCTION USING POLOXAMERS - The present invention relates to a method for transducing a target cell, the method comprising the step of contacting a target cell with a retroviral vector and a poloxamer having a molecular weight of 12.8 kDa to about 15 kDa. Further, the invention relates to the use of a poloxamer as defined herein, optionally in combination with a polycationic substance as defined herein, for transducing a target cell with a retroviral vector and a kit comprising a retroviral vector, a poloxamer as defined herein and, optionally, instructions for use. | 03-05-2015 |
20150087068 | METHODS OF GENETICALLY MODIFYING ANIMAL CELLS - This invention relates to improved methods of genetically modifying animal cells by decreasing the distance between cells and genetic modification agents in order to increase the efficiency of genetic modification and/or reduce use of gene modification agents. | 03-26-2015 |
20150093831 | CONSTRUCTION OF FULLY-DELETED ADENOVIRUS-BASED GENE DELIVERY VECTORS AND USES THEREOF - The embodiments disclosed herein relate to the construction of fully-deleted Adenovirus-based gene delivery vectors packaged without helper Adenovirus, and more particularly to their use in gene therapy for gene and protein expression, vaccine development, and immunosuppressive therapy for allogeneic transplantation. In an embodiment, a method for propagating an adenoviral vector includes (a) providing an Adenovirus packaging cell line; (b) transfecting a fully-deleted Adenoviral vector construct into the cell line; and optionally (c) transfecting a packaging construct into the cell line, wherein the fully-deleted Adenoviral vector construct and optionally the packaging construct can transfect the Adenovirus packaging cell line resulting in the encapsidation of a fully-deleted Adenoviral vector independent of helper Adenovirus. In an embodiment, a target cell is transduced with the encapsidated fully-deleted Adenoviral vector for treating a condition, disease or a disorder. | 04-02-2015 |
20150140663 | IN VITRO RECONSTITUTED PLANT VIRUS CAPSIDS FOR DELIVERING RNA GENES TO MAMMALIAN CELLS - The invention provides compositions of matter comprising a cowpea chlorotic mottle virus capsid protein (CCMV CP) and a ribonucleic acid, as well as methods for using such compositions. In such compositions, the cowpea chlorotic mottle virus capsid protein envelops the ribonucleic acid so as to for a capsid that can inhibit the degradation of the ribonucleic acid (e.g. by RNAses). A method of delivering a ribonucleic acid into the cytoplasm of a mammalian cell is also provided. Typically, the method comprises the steps of combining the mammalian cell with a composition of matter described herein under conditions selected to allow the cowpea chlorotic mottle virus capsid to contact the mammalian cell and deliver the ribonucleic acid into the cytoplasm of a mammalian cell. | 05-21-2015 |
20150315610 | AAV VARIANT - The invention provides an AAV particle containing an adeno-associated viral (AAV) capsid protein having an amino acid sequence selected from the group consisting of SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 24, and SEQ ID NO: 30 of the sequence listing; a nucleic acid that encodes this capsid protein; DNA containing this nucleic acid; a cell containing this DNA; and a method for producing this cell. | 11-05-2015 |
20150320803 | Method for production of anti-tumor TRAIL protein - A method for production of anti-tumor TRAIL includes inserting a TRAIL molecule, encoded by a viral vector irreversibly derived from a cell line, into a carrier cell, thereby obtaining a stably TRAIL-producing carrier cell, and wherein the TRAIL molecule includes a soluble molecule. | 11-12-2015 |
20150376577 | Methods for the Release of Virus-Like Particles - The present invention relates to methods for the release of baculovirus-expressed Virus-like Particles (VLP's) of non-enveloped viruses from insect cells. | 12-31-2015 |
20160010064 | MUTANT VACCINIA VIRUS STRAINS, USES THEREOF AND METHOD OF PRODUCING THE SAME | 01-14-2016 |
20160032317 | COMPOSITIONS AND METHODS FOR REPROGRAMMING HEMATOPOIETIC STEM CELL LINEAGES - Provided herein are compositions, methods, and kits for hematopoietic stem cell induction or for reprogramming cells to the multipotent state of hematopoietic stem cells. In some embodiments, the compositions comprise at least one HSC inducing factor. Such compositions, methods and kits can be used for inducing hematopoietic stem cells in vitro, ex vivo, or in vivo, as described herein, and these induced hematopoietic stem cells can be used in regenerative medicine applications and therapies. | 02-04-2016 |
20160040188 | Intergenic Sites Between Conserved Genes in the Genome of Modified Vaccinia Ankara (MVA) Vaccinia Virus - The present invention relates to new insertion sites useful for the integration of exogenous sequences into an intergenic region (IGR) of a vaccinia virus genome, where the IGR is located between or is flanked by two adjacent open reading frames (ORFs) of the vaccinia virus genome, and where the ORFs correspond to conserved genes, and to related plasmid vectors useful to insert exogenous DNA into the genome of a vaccinia virus, and further to recombinant vaccinia viruses comprising an exogenous sequence inserted into said new insertion site as a medicine or vaccine. | 02-11-2016 |
20160102297 | RESTRICTIVE INVERTED TERMINAL REPEATS FOR VIRAL VECTORS - This invention relates to modified parvovirus inverted terminal repeats (ITRs) that do not functionally interact with wild-type large Rep proteins, synthetic Rep proteins that functionally interact with the modified ITRs, and methods of using the same for delivery of nucleic acids to a cell or a subject. The modifications provide a novel Rep-ITR interaction that limits vector mobilization, increasing the safety of viral vectors. | 04-14-2016 |
20160138047 | IMPROVED POLYNUCLEOTIDE SEQUENCES ENCODING TALE REPEATS - The present invention is in the field of the gene editing molecular tools. The present invention relates to rewritten nucleic acid sequences encoding repeated DNA recognition motifs of TALE (Transcription Activator-Like Effector) proteins. These nucleic acid sequences allow assembly and cloning of TALE repeats in any type of vectors, especially viral vectors. The invention thereby contributes to improving gene targeting in cells using TALE derived proteins, in particular for genetic regulation or modification. The present invention is particularly drawn to virus mediated transformation methods, by providing vectors, compositions and kits including said new nucleic acid sequences. | 05-19-2016 |
20160184362 | METHODS FOR ENGINEERING T CELLS FOR IMMUNOTHERAPY BY USING RNA-GUIDED CAS NUCLEASE SYSTEM - The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections. | 06-30-2016 |
20160376558 | METHOD FOR INDUCING PLURIPOTENCY IN A HEMATOPOIETIC CELL - There is provided a method of inducing pluripotency in a hematopoietic cell. The method comprises providing a blood sample that has been collected from a subject in the absence of any polysaccharide preparation used for separating blood components. The sample is depleted of red blood cells by treating the sample with a hypotonic erythrocyte lysis buffer, in the absence of any polysaccharide preparation used for separating blood components, thus obtaining a remaining cell population. The remaining cell population in the sample is expanded in a hematopoietic expansion medium to obtain an expanded cell population that contains CD71+ cells, and the expanded cell population containing the CD71+ cells is then cultured in the presence of Oct4, Sox2, and Klf4, and optionally c-MYC, in human embryonic stem cell medium to induce pluripotency. | 12-29-2016 |
20180021364 | CENTRAL NERVOUS SYSTEM TARGETING POLYNUCLEOTIDES | 01-25-2018 |